首页 | 本学科首页   官方微博 | 高级检索  
     

三维适形放疗联合替莫唑胺对恶性脑胶质瘤疗效评价
引用本文:王琼,王南瑶,茅卫东,顾小卫.三维适形放疗联合替莫唑胺对恶性脑胶质瘤疗效评价[J].中国现代医生,2008,46(34):35-36.
作者姓名:王琼  王南瑶  茅卫东  顾小卫
作者单位:东南大学医学院附属江阴人民医院,江苏江阴,214400
摘    要:目的观察恶性脑胶质瘤术后三维适形放疗联合替莫唑胺(TMz)的近期疗效和不良反应。方法选择我院收治20例术后病理证实为恶性胶质瘤的病人,行三维适形放疗,2.0Gy/(次·d),DT55~65Gy。同时采用替莫唑胺化疗,并进行6个周期的化疗。结果本组CR为30%(6/20),PR为50%(10/20),有效率为80%,6个月无病进展生存率为75%(15/20),1年无病进展生存率为50%(10/20),1年生存率为70%(14/20)。结论三维适形放疗联合替莫唑胺治疗恶性脑胶质瘤的近期疗效良好,患者对治疗耐受性较好。

关 键 词:脑胶质瘤  三维适形放疗  替莫唑胺  生存时间  安全性

Evaluation of the Efficacy in Three-dimensional Conformal Radiotherapy with Temozolomide in Treatment of Postoperative Malignant Glioma
Authors:WANG Qiong  WANG Nanyao  MAO Weidong  GU Xiaowei
Affiliation:(Department of Oncology, Jiangyin People' s Hospital, Southeast University, Jiangsu 214400)
Abstract:Objective To observe the clinical efficacy and side effects of three-dimensional conformal radiotherapy concomitant with temozolomide in the treatment of postoperative malignant glioma in Chinese patients. Methods 20 po.stoperative patients with pathologically confirmed malignant glioma previously treated with partial resection of the tumor received three dimensional conformal radiotherapy with concomitant and adjuvant temozolomide chemotherapy. Results The overall response rates(CR+PR) were 80%, including six(30%) patients with complete responses and ten(50%) partial responses. Progression-free survival rate was75%( 15/20)at 6 months and 50%(10/20) at 1 year respectively. The one-year survival rate was 70%(14/20). Conclusion Three dimensional conformal radiotherapy with temozolomide in the treatment of postoperative malignant gliomas demonstrates good tolerance and achieved fair short-term efficacy.
Keywords:Malignant glioma  Three dimensional conformal radiotherapy  Temozolomide  Survival time  Safety
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号